Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of First Subject Enrollment in the Phase III Clinical Trial of BL-B01D1/iza-bren for the Treatment of Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-Based Chemotherapy

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

On 6ix: 6ix.com/news/sichuan-biokin-pharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-the-completion-of-first-subject-enrollment-in-the-phase-iii-clinical-trial-of-bl-b01d1iza-bren-for-the-treatment-of-locally-advanced-or-metastatic-biliary-tract-cancer-after-failure-of-platinum-based-chemotherapy

Announcement on Voluntary Disclosure of the Completion of First Subject Enrollment in the Phase III Clinical Trial of BL-B01D1/iza-bren for the Treatment of Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-Based Chemotherapy

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Sichuan Biokin Pharmaceutical

Later from Sichuan Biokin Pharmaceutical

All Sichuan Biokin Pharmaceutical news releases